Back to School: How biopharma can reboot drug development. Access exclusive analysis here

More (and less) than meets the eye

More (and less) than meets the eye

Despite its dwindling cash position, NeoPharm Pharmaceuticals Inc. (NEO) has reversed its financial situation through a deal with Pharmacia & Upjohn Inc. covering NEO's Liposomal Encapsulated Paclitaxel (LEP) and Liposomal Encapsulated Doxorubicin (LED).

Although the announcement last week

Read the full 447 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE